title: Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.
abstract: HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.
authors.affiliation: Duke Human Vaccine Institute, Durham, NC 27710, USA.
authors.forename: Nicole L
authors.initials: NL
authors.lastname: Yates
authors.forename: Hua-Xin
authors.initials: HX
authors.lastname: Liao
authors.forename: Youyi
authors.initials: Y
authors.lastname: Fong
authors.forename: Allan
authors.initials: A
authors.lastname: deCamp
authors.forename: Nathan A
authors.initials: NA
authors.lastname: Vandergrift
authors.forename: William T
authors.initials: WT
authors.lastname: Williams
authors.forename: S Munir
authors.initials: SM
authors.lastname: Alam
authors.forename: Guido
authors.initials: G
authors.lastname: Ferrari
authors.forename: Zhi-yong
authors.initials: ZY
authors.lastname: Yang
authors.forename: Kelly E
authors.initials: KE
authors.lastname: Seaton
authors.forename: Phillip W
authors.initials: PW
authors.lastname: Berman
authors.forename: Michael D
authors.initials: MD
authors.lastname: Alpert
authors.forename: David T
authors.initials: DT
authors.lastname: Evans
authors.forename: Robert J
authors.initials: RJ
authors.lastname: O'Connell
authors.forename: Donald
authors.initials: D
authors.lastname: Francis
authors.forename: Faruk
authors.initials: F
authors.lastname: Sinangil
authors.forename: Carter
authors.initials: C
authors.lastname: Lee
authors.forename: Sorachai
authors.initials: S
authors.lastname: Nitayaphan
authors.forename: Supachai
authors.initials: S
authors.lastname: Rerks-Ngarm
authors.forename: Jaranit
authors.initials: J
authors.lastname: Kaewkungwal
authors.forename: Punnee
authors.initials: P
authors.lastname: Pitisuttithum
authors.forename: James
authors.initials: J
authors.lastname: Tartaglia
authors.forename: Abraham
authors.initials: A
authors.lastname: Pinter
authors.forename: Susan
authors.initials: S
authors.lastname: Zolla-Pazner
authors.forename: Peter B
authors.initials: PB
authors.lastname: Gilbert
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Nabel
authors.forename: Nelson L
authors.initials: NL
authors.lastname: Michael
authors.forename: Jerome H
authors.initials: JH
authors.lastname: Kim
authors.forename: David C
authors.initials: DC
authors.lastname: Montefiori
authors.forename: Barton F
authors.initials: BF
authors.lastname: Haynes
authors.forename: Georgia D
authors.initials: GD
authors.lastname: Tomaras
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D015483:HIV Antibodies / Q000096:biosynthesis / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies; D007074:Immunoglobulin G